Patent classifications
A61K51/085
Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.
Enhanced in Vivo Targeting of Site-Specific Drugs
The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
Radiofluorination method
The present invention relates to a method of labelling biological molecules with .sup.18F, via attachment to fluorine to a macrocyclic metal complex of a non-radioactive metal, where the metal complex is conjugated to the biological molecule. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.
RADIOPHARMACEUTICALS AND METHODS OF USE THEREOF
Targeted pharmaceuticals, particularly targeted radiopharmaceuticals, are provided which possess extended tumor retention time.
Enhanced in Vivo Targeting of Radiolabelled Peptides With the Means of Enzyme Inhibitors
The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
Vinylsulfone-based 18F-labeling compositions and methods and uses thereof
A thio-selective radioactive labeling agent has the following general formula:
*R-L-VS, wherein said *R is a radioisotope, L is a linking group, and VS is a vinylsulfone functional group.
Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
Radiopharmaceuticals and methods of use thereof
Targeted pharmaceuticals, particularly targeted radiopharmaceuticals, are provided which possess extended tumor retention time.